Efavirenz


Article Author:
Jessica Yee


Article Editor:
Charles Preuss


Editors In Chief:
Kranthi Sitammagari
Mayank Singhal


Managing Editors:
Avais Raja
Orawan Chaigasame
Carrie Smith
Abdul Waheed
Khalid Alsayouri
Kyle Blair
Trevor Nezwek
Radia Jamil
Erin Hughes
Patrick Le
Anoosh Zafar Gondal
Saad Nazir
William Gossman
Hassam Zulfiqar
Navid Mahabadi
Hussain Sajjad
Steve Bhimji
Muhammad Hashmi
John Shell
Matthew Varacallo
Heba Mahdy
Ahmad Malik
Sarosh Vaqar
Mark Pellegrini
James Hughes
Beata Beatty
Daniyal Ameen
Altif Muneeb
Beenish Sohail
Nazia Sadiq
Hajira Basit
Phillip Hynes
Komal Shaheen
Sandeep Sekhon


Updated:
5/30/2019 12:15:11 AM

Indications

Efavirenz is an FDA-approved medication used for the treatment and prevention of HIV. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI). Like the majority of other NNRTI agents, its most common use is in combination with other agents with different mechanisms of action in antiretroviral therapy (ART) regimens. Due to its unfavorable side effect profile, it has fallen somewhat out of favor.[1]

  • FDA-labeled indications
    • HIV infection
  • Non-FDA labeled indications
    • HIV infection prophylaxis (occupational exposure, perinatal transmission)

Mechanism of Action

Efavirenz is a non-nucleoside reverse transcriptase inhibitor drug (NNRTI). It binds to a non-catalytic site of the HIV reverse transcription enzyme, thereby inhibiting its activity. This action consequently blocks DNA polymerase activities, including HIV replication. Though therapeutic drug concentration monitoring is not necessary for efavirenz, it is essential to achieve adequate serum concentrations. Low concentrations are associated with virologic failure, while higher concentrations are associated with increased adverse effects such as sleep disorders.[2]

The administration of efavirenz with food has shown to increase the serum concentrations and the incidence of side effects. For this reason, patients should not take efavirenz with food.[3] Peak concentrations are reached by 5 hours following a single oral dose, with steady-state plasma concentrations achieved in 6 to 7 days. The half-life of efavirenz is roughly 45 hours, making once daily dosing suitable. Efavirenz is highly protein bound to human plasma proteins, predominantly albumin. Efavirenz converts to inactive hydroxylated metabolites by the action of the CYP3A4 enzyme.[4] 

It is available in combination with other antiviral medications.[5]

Administration

Efavirenz is available by prescription only, and it is available as an oral capsule and an oral tablet. It is also available as a component of two combination drugs: efavirenz, emtricitabine, and tenofovir disoproxil fumarate, and efavirenz, lamivudine, and tenofovir disoproxil fumarate. The capsules are available as 200 mg and 50 mg, while the tablets are available as 600 mg. The recommended adult dose is 600 mg per day, but there has been data showing that 400 mg per day yields equivalent outcomes with fewer side effects.[6]

The manufacturer recommends no renal dose adjustments. No dose adjustments are necessary for mild hepatic impairment (Child-Pugh class A), but caution is advisable. Efavirenz is not recommended in patients with moderate to severe impairment (Child-Pugh class B or C).

Efavirenz dosing should be on an empty stomach, as increased efavirenz serum concentrations occur when taken with food. Increased serum concentrations can lead to increased adverse effects.[7] 

Adverse Effects

NNRTIs as a drug class are commonly associated with central nervous system (CNS) effects. Among these are impaired concentration, vivid or abnormal dreams, insomnia, suicidal ideation, nausea, and vomiting.[8] Patients who experience these adverse effects are more likely to be non-adherent and discontinue their antiretroviral therapy, leading to virologic failure.[9] These symptoms typically arise in the first few days of treatment and decline within a few weeks of continued treatment.[4]

Like the majority of the NNRTIs, efavirenz correlates with a wide array of drug interactions due to the phase I cytochrome P450 (CYP) enzymes. Efavirenz is a substrate, inducer, and inhibitor of CYP3A4.[10] 

Lipodystrophy is also a class-wide effect of NNRTIs and may occur during treatment with efavirenz.[4]

Contraindications

The use of efavirenz is contraindicated in patients with previously documented hypersensitivity to efavirenz and patients concurrently receiving elbasvir/grazoprevir due to a CYP3A4 interaction. Efavirenz acts as a CYP3A4 inducer, in this case, by decreasing the serum concentrations of grazoprevir.[11] The use of efavirenz is also contraindicated in pregnant women in the first trimester due to reports of neural tube defects. 

Monitoring

As one of the predominant side effects of efavirenz, psychiatric effects require monitoring in all patients. In the event that these symptoms do occur, the prescriber can attempt dose adjustments before changing medications. Due to the potential for hepatotoxicity, serum transaminases also require periodic monitoring.

Toxicity

Toxicity of this drug is generally related to the adverse effects associated with it, which are relative to serum concentrations. Overdose is uncommon and life-threatening sequelae from acute overdose are rare. There is no available antidote for efavirenz overdose.

Enhancing Healthcare Team Outcomes

Treatment with efavirenz can significantly improve the quality of life of patients infected with HIV, but its efficacy heavily relies on patient adherence. The neurologic side effects associated with efavirenz cause some patients to discontinue therapy. It is crucial that an interdisciplinary team of healthcare providers becomes actively involved with the care of their HIV-positive patients. Key members of the team include pharmacists, physicians, nurses, and social workers. Obstacles to successful ART may include a lack of social support and financial burden of therapy. Healthcare providers play a critical role in providing counseling regarding methods of coping with these side effects and promoting medication adherence. Identifying appropriate opportunities for members of each discipline to provide care and encouragement is crucial to successful ART.[12]

The following are recommendations for healthcare providers to assist in increasing successful outcomes in patients diagnosed with HIV on ART[13]:

  • Monitoring of successful entry into HIV care is recommended for individuals diagnosed with HIV (Level IIA)
    • Entry into care, defined as a visit with an HIV care provider, has demonstrated correlations with improved survival. 
  • Providers should obtain self-reported adherence routinely. (Level IIA)
    • Healthcare providers should ask patients about their adherence at appointments.
  • Pharmacy refill data is recommended for adherence monitoring if medication refills are not automatically sent to patients. (Level IIB)
    • Pharmacy refill data can be used to confirm self-reported adherence.
  • Switching treatment-experienced patients receiving complex or poorly tolerated regimens to simpler once-daily regimens is recommended if regimens have equivalent efficacy. (Level IIIB)
    • A higher pill burden is associated with lower adherence. Discussing with the patient about pill burden can identify an opportunity for improving adherence.
  • Individual one-on-one ART education is recommended (Level IIA)
    • Counseling, skills-building, and education have been shown to increase adherence rates.
  • Multidisciplinary education and counseling intervention approaches are recommended (Level IIIB)
    • Interprofessional teams can provide education regarding multiple factors that affect adherence.
  • Case management is recommended to minimize the number of adherence barriers in the homeless (Level IIIB)
    • Assistance in acquiring mental health and substance abuse treatment and housing accommodations can significantly improve outcomes.

In summary, efavirenz therapy, as with all ART,  requires an interprofessional team approach, including physicians, specialists, specialty-trained nurses, and pharmacists, all collaborating across disciplines to achieve optimal patient results. [Level V]


Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Efavirenz - Questions

Take a quiz of the questions on this article.

Take Quiz
Which of the following HAART medications is NOT recommended for use in children under 3 years of age?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 16-year-old female with a past medical history of schizophrenia has been diagnosed with HIV. The attending clinician decides not to give the patient efavirenz/emtricitabine/tenofovir. What is the reasoning behind this decision?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 40-year-old male with the past medical history significant for HIV and diabetes. He consumes fast-food for at least 2 meals per day. His medication list includes metformin 500mg twice daily, glimepiride 2mg once daily, atorvastatin 40mg once daily and efavirenz/emtricitabine/tenofovir once daily. Which of the following is a vital counseling point regarding his ART regimen?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A virus with K103N mutation is resistant to which of the following antiretrovirals?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 16-year-old male presents with a chief complaint of vivid, abnormal dreams. He has a past medical history significant for HIV. Which of the following non-nucleoside reverse transcriptase inhibitors could be responsible for the patient's chief complaint?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
An 18-year-old man is diagnosed with HIV-1 infection. The patient receives treatment with efavirenz/emtricitabine/tenofovir disoproxil fumarate, as 1 tablet once a day. What is the mechanism of action of efavirenz?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up

Efavirenz - References

References

Desta Z,Gammal RS,Gong L,Whirl-Carrillo M,Gaur AH,Sukasem C,Hockings J,Myers A,Swart M,Tyndale R,Masimirembwa C,Iwuchukwu OF,Chirwa S,Lennox J,Gaedigk A,Klein T,Haas DW, Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-containing Antiretroviral Therapy. Clinical pharmacology and therapeutics. 2019 Apr 21;     [PubMed]
Homkham N,Cressey TR,Bouazza N,Ingsrisawang L,Techakunakorn P,Mekmullica J,Borkird T,Puangsombat A,Na-Rajsima S,Treluyer JM,Urien S,Jourdain G, Role of efavirenz plasma concentrations on long-term HIV suppression and immune restoration in HIV-infected children. PloS one. 2019;     [PubMed]
Apostolova N,Blas-Garcia A,Galindo MJ,Esplugues JV, Efavirenz: What is known about the cellular mechanisms responsible for its adverse effects. European journal of pharmacology. 2017 Oct 5;     [PubMed]
Rice DP Jr,Faragon JJ,Banks S,Chirch LM, HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals. Journal of clinical and translational hepatology. 2016 Sep 28;     [PubMed]
Chendi BH,Okomo Assoumou MC,Jacobs GB,Yekwa EL,Lyonga E,Mesembe M,Eyoh A,Ikomey GM, Rate of viral load change and adherence of HIV adult patients treated with Efavirenz or Nevirapine antiretroviral regimens at 24 and 48 weeks in Yaoundé, Cameroon: a longitudinal cohort study. BMC infectious diseases. 2019 Feb 26;     [PubMed]
Caniglia EC,Phillips A,Porter K,Sabin CA,Winston A,Logan R,Gill J,Vandenhende MA,Barger D,Lodi S,Moreno S,Arribas JR,Pacheco A,Cardoso SW,Chrysos G,Gogos C,Abgrall S,Costagliola D,Meyer L,Seng R,van Sighem A,Reiss P,Muga R,Hoyos SP,Braun D,Hauser C,Barrufet P,Leyes M,Tate J,Justice A,Hernán MA, Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions. Journal of acquired immune deficiency syndromes (1999). 2018 Jan 1     [PubMed]
McDonagh EM,Lau JL,Alvarellos ML,Altman RB,Klein TE, PharmGKB summary: Efavirenz pathway, pharmacokinetics. Pharmacogenetics and genomics. 2015 Jul     [PubMed]
Robarge JD,Metzger IF,Lu J,Thong N,Skaar TC,Desta Z,Bies RR, Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition. Antimicrobial agents and chemotherapy. 2017 Jan     [PubMed]
    [PubMed]
    [PubMed]
    [PubMed]
    [PubMed]
    [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of PA-Hospital Medicine. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for PA-Hospital Medicine, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in PA-Hospital Medicine, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of PA-Hospital Medicine. When it is time for the PA-Hospital Medicine board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study PA-Hospital Medicine.